Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...
Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...
Despite maintaining its full-year outlook, Medtronic slips in pre-market trading following a revenue miss in its Q3 report.
Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.
Medtronic PLC’s stock fell 7.3% as the worst performer in the S&P 500 on Tuesday after the medical-products company’s ...
Product-wise, Medtronic's cardiovascular, neuroscience, and surgical segments comprise most of the business, with a minor contribution from its diabetes unit. That diversity helps ensure stability ...
Medtronic stock was down stock was down today after its third-quarter revenue slightly missed the Wall Street analyst consensus.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback